Interpretation of 2018 update of the EULAR recommendations for the management of Behcet's syndrome

doi:10.3877/cma.j.issn.2095-2007.2018.04.001

Abstract

Abstract:

Behcet uveitis (BU) is one of the most common posterior/pan-uveitis entities in China with poor prognosis and high rate of blindness, and represent one of the most challenging issue facing uveitis specialists. Treatment modalities for BU include corticosteroids, immunomodulatory treatments, anti-tumor necrosis factorαantibodies and interferon α. The present article provides a mini review on the above-mentioned treatment modalities for BU, followed by interpretation of and personal commentary on the recently published "2018 updates of the EULAR recommendations for the managements of Behcet’s syndrome" .

Key words: Behcet syndrome, Uveitis, Treatment, EULAR, Interferon-α

Chan Zhao, Meifen Zhang. Interpretation of 2018 update of the EULAR recommendations for the management of Behcet's syndrome[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2018, 08(04): 145-150.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2018.04.001

https://zhykyxzz.cma-cmc.com.cn/EN/Y2018/V08/I04/145

References 69

[1]	Krause I, Weinberger A. Behcet's disease[J]. Curr Opin Rheumatol，2008，20(1):82-87.
[2]	Yates PA, Michelson JB. Behcet disease[J]. Int Ophthalmol Clin，2006，46(2):209-233.
[3]	彭劲民，张卓莉，董怡. 白塞病173例的临床特点分析[J]. 中华全科医师杂志，2006，5(3):154-157.
[4]	Yang P, Fang W, Meng Q, et al. Clinical features of chinese patients with Behcet's disease[J]. Ophthalmology，2008，115(2):312-318.
[5]	Esatoglu SN, Hatemi G, Salihoglu A, et al.A reappraisal of the association between Behcet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review[J]．Clin Exp Rheumatol，2015，33(6 Suppl 94):S145-151.
[6]	Gao N, Han W, Ci WP, et al.Clinical data analysis of cardiovascular involvement in Behcet's disease[J]．Zhonghua Yi Xue Za Zhi，2016，96(19):1523-1526.
[7]	Wang H, Guo X, Tian Z, et al.Intracardiac thrombus in patients with Behcet's disease: clinical correlates, imaging features, and outcome: a retrospective, single－center experience[J]．Clin Rheumatol，2016，35(10):2501-2507.
[8]	Zhang F, Su M, Zhang B, et al.Clinical features and disease activity index of Behcet's disease[J]．Zhonghua Yi Xue Za Zhi，2015，95(31):2547-2550.
[9]	杨培增，王红，黄祥坤，等. 葡萄膜炎的临床类型及病因探讨[J]. 中华眼底病杂志，2002，18(4):4-6.
[10]	LeHoang P. The gold standard of noninfectious uveitis: corticosteroids[J]. Dev Ophthalmol ，2012，51:7-28.
[11]	Stanbury RM, Graham EM. Systemic corticosteroid therapy－side effects and their management[J]. Br J Ophthalmol，1998，82(6):704-708.
[12]	Kruh J, Foster CS. The philosophy of treatment of uveitis: past, present and future[J]. Dev Ophthalmol，2012，51:1-6.
[13]	Foster CS, Kothari S, Anesi SD, et al.The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management[J]．Surv Ophthalmol，2016，61(1):1-17.
[14]	Kruh J, Foster CS.Corticosteroid－sparing agents: conventional systemic immunosuppressants[J]．Dev Ophthalmol，2012，51:29-46.
[15]	Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel[J]. Am J Ophthalmol，2000，130(4):492-513.
[16]	Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease[J]. Surv Ophthalmol，2005, 50(4):297-350.
[17]	Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight－threatening panuveitis in Behcet's disease[J]. Lancet，2001，358(9278):295-296.
[18]	Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight－threatening ocular inflammation in Adamantiades－Behcet disease[J]. Ann Intern Med，2004，140(5):404-406.
[19]	Tugal－Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open－label trial[J]. Arthritis Rheum，2005，52(8):2478-2484.
[20]	Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4－week study[J]. Rheumatology (Oxford)，2011，50(3):593-597.
[21]	Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease[J]. Clin Exp Ophthalmol，2006，34(4):365-374.
[22]	Garcia－Pous M, Hernández－Garfella ML, Díaz－Llopis M．Treatment of chronic orbital myositis with daclizumab[J]．Can J Ophthalmol，2007，42(1):156-157.
[23]	Silpa－Archa S, Oray M, Preble JM, et al.Outcome of tocilizumab treatment in refractory ocular inflammatory diseases[J]．Acta Ophthalmol，2016，94(6):e400-406.
[24]	Mesquida M, Molins B, Lloren V, et al.Twenty－four month follow－up of tocilizumab therapy for refractory uveitis－related macular edema[J]．Retina. 2018，38(7):1361-1370.
[25]	Calvo－Río V, Blanco R, Santos－Gómez M, et al.Efficacy of Anti－IL6－Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review[J]．Ocul Immunol Inflamm，2017，25(5):604-609.
[26]	Posarelli C, Arapi I, Figus M, et al. Biologic agents in inflammatory eye disease[J]. J Ophthalmic Vis Res，2011，6(4):309-316.
[27]	Neri P, Arapi I, Nicolai M，et al.Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile[J]．Curr Drug Saf，2016，11(1):47-54.
[28]	Zhao C, Zhang M．Immunosuppressive Treatment of Non－infectious Uveitis: History and Current Choices[J]．Chin Med Sci J，2017，32(1):48-61.
[29]	Takeuchi M. A systematic review of biologics for the treatment of noninfectious uveitis[J]. Immunotherapy，2013，5(1):91-102.
[30]	Lee K, Bajwa A, Freitas－Neto CA, et al.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II[J]．Expert Opin Biol Ther，2014，14(11):1651-1666.
[31]	Gueudry J, LeHoang P, Bodaghi B. Anti－tumor necrosis factor－alpha agents in noninfectious uveitis[J]. Dev Ophthalmol，2012，51:63-78.
[32]	Leclercq M, Le Besnerais M, Langlois V, et al.Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti－tumor necrosis factor－alpha therapy: two cases report and literature review[J]．Clin Rheumatol，2018，37(3):849-853.
[33]	Mushtaq B, Saeed T, Situnayake RD, et al. Adalimumab for sight－threatening uveitis in Behcet's disease[J]. Eye (Lond)，2007，21(6):824-825.
[34]	Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behcet's uveitis: a retrospective long－term follow－up study[J]. Clin Exp Rheumatol, 2014，32(4 Suppl 84):S58-62.
[35]	Atienza－Mateo B, Calvo－Río V, Beltrán E, et al.Anti－interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet's disease: multicentre retrospective study[J]．Rheumatology (Oxford). 2018，57(5):856-864.
[36]	Fabiani C, Vitale A, Emmi G, et al.Efficacy and safety of adalimumab in Behcet's disease－related uveitis: a multicenter retrospective observational study[J]．Clin Rheumatol，2017，36(1):183-189.
[37]	Díaz－Llopis M, Salom D, Garcia－de－Vicuña C, et al.Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients[J]．Ophthalmology，2012 ，119(8):1575-1581.
[38]	Calvo－Río V, Blanco R, Beltrán E, et al.Anti－TNF－α therapy in patients with refractory uveitis due to Behcet's disease: a 1－year follow－up study of 124 patients[J]．Rheumatology (Oxford)，2014，53(12):2223-2231.
[39]	Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab－allergic patient with severe Behcet disease－related uveitis[J]. Rheumatol Int，2011，31(2):243-245.
[40]	Vallet H, Seve P, Biard L, et al. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network[J]. Arthritis Rheumatol, 2016，68(6):1522-1530.
[41]	Scheinfeld N. Adalimumab: a review of side effects[J]. Expert Opin Drug Saf，2005，4(4):637-641.
[42]	Levy－Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti－tumor necrosis factor biologic agents in patients with ocular inflammatory disorders[J]. Ophthalmology，2014，121(3):785-796.
[43]	张美芬，赵潺，温鑫，等. 依那西普治疗复发性Behcet病葡萄膜炎的短期疗效和安全性研究[J]. 中华眼科杂志，2010，46(2):145-150.
[44]	Palucka AK, Blanck JP, Bennett L, et al. Cross－regulation of TNF and IFN－alpha in autoimmune diseases[J]. Proc Natl Acad Sci U S A，2005，102(9):3372-3377.
[45]	Plskova J, Greiner K, Muckersie E, et al. Interferon－alpha: a key factor in autoimmune disease[J]. Invest Ophthalmol Vis Sci，2006，47(9):3946-3950.
[46]	Kotter I, Eckstein AK, Stubiger N, et al. Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study[J]. Br J Ophthalmol，1998，82(5):488-94.
[47]	Kötter I, Eckstein AK, Stübiger N, et al.Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study[J]．Br J Ophthalmol，1998，82(5):488-494.
[48]	Kötter I, Günaydin I, Zierhut M, et al.The use of interferon alpha in Behcet disease: review of the literature[J]．Semin Arthritis Rheum，2004，33(5):320-335.
[49]	Tugal－Tutkun I, Güney－Tefekli E, Urgancioglu M．Results of interferon－alfa therapy in patients with Behcet uveitis[J]．Graefes Arch Clin Exp Ophthalmol，2006，244(12):1692-1695.
[50]	Sobaci G, Erdem U, Durukan AH, et al.Safety and effectiveness of interferon alpha－2a in treatment of patients with Behcet's uveitis refractory to conventional treatments[J]．Ophthalmology，2010，117(7):1430-1435.
[51]	Hasanreisoglu M, Cubuk MO, Ozdek S, et al. Interferon Alpha－2a Therapy in Patients with Refractory Behcet Uveitis[J]. Ocul Immunol Inflamm, 2017，25(1):71-75.
[52]	Diwo E, Gueudry J, Saadoun D, et al. Long－term Efficacy of Interferon in Severe Uveitis Associated with Behcet Disease[J]. Ocul Immunol Inflamm，2017，25(1):76-84.
[53]	Gueudry J, Wechsler B, Terrada C, et al.Long－term efficacy and safety of low－dose interferon alpha2a therapy in severe uveitis associated with Behcet disease[J]．Am J Ophthalmol，2008 ，146(6):837-844.
[54]	Yang P, Huang G, Du L, et al. Long－Term Efficacy and Safety of Interferon Alpha－2a in the Treatment of Chinese Patients with Behcet's Uveitis Not Responding to Conventional Therapy[J]. Ocular Immunology & Inflammation, 2017，17(2):1-8.
[55]	Tan HY, Agarwal A, Lee CS, et al. Management of noninfectious posterior uveitis with intravitreal drug therapy[J]. Clin Ophthalmol, 2016，10:1983-2020.
[56]	Ibrahim MA, Sepah YJ, Watters A, et al.One－Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis[J]．Transl Vis Sci Technol，2015，4(2):4.
[57]	Blair J, Barry R, Moore DJ, et al.A Comprehensive Review of mTOR－Inhibiting Pharmacotherapy for the Treatment of Non－Infectious Uveitis[J]．Curr Pharm Des，2017，23(20):3005-3014.
[58]	Nguyen QD, Merrill PT, Clark WL, et al.Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double－masKed Uveitis TReAtment (SAKURA)[J]．Ophthalmology，2016，123(11):2413-2423.
[59]	Lescrauwaet B, Miserocchi E, Thurau S, et al.Association Between Visual Function Response and Reduction of Inflammation in Noninfectious Uveitis of the Posterior Segment[J]．Invest Ophthalmol Vis Sci，2017，58(9):3555-3562.
[60]	Herbort CP, Tugal－Tutkun I, Neri P, et al.Failure to Integrate Quantitative Measurement Methods of Ocular Inflammation Hampers Clinical Practice and Trials on New Therapies for Posterior Uveitis[J]．J Ocul Pharmacol Ther，2017，33(4):263-277.
[61]	Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease[J]. J Ocul Pharmacol Ther, 2007，23(4):395-401.
[62]	Park UC, Park JH, Yu HG. Long－term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behcet disease[J]. Ocul Immunol Inflamm, 2014，22(1):27-33.
[63]	Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight－threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients[J]. Am J Ophthalmol, 2012，154(3):534-541.
[64]	Evereklioglu C．Ocular Behcet disease: current therapeutic approaches[J]．Curr Opin Ophthalmol，2011，22(6):508-516.
[65]	Rifkin LM, Birnbaum AD, Goldstein DA.TNF inhibition for ophthalmic indications: current status and outlook[J]．BioDrugs，2013，27(4):347-357.
[66]	Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease[J]. Ann Rheum Dis，2008，67(12):1656-1662.
[67]	Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome[J]. Ann Rheum Dis，2018，77(6):808-818.
[68]	Santos－Gómez M, Calvo－Río V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet's disease: results of a multicentre open－label study[J]. Clin Exp Rheumatol, 2016，34(6 Suppl 102):S34-S40.
[69]	Borrás－Blasco J, Casterá DE, Cortes X, et al. Effectiveness of infliximab, adalimumab and golimumab for non－infectious refractory uveitis in adults[J]. Int J Clin Pharmacol Ther, 2015，53(5):377-390.

Please choose a citation manager

Content to export